Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acids and salts thereof
Reexamination Certificate
2011-05-17
2011-05-17
Katakam, Sudhakar (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acids and salts thereof
C514S475000, C514S741000, C560S100000, C568S715000, C568S722000
Reexamination Certificate
active
07943795
ABSTRACT:
The present invention relates to novel, non-secosteroidal, phenyl-naphthalene compounds of Formula (I): wherein R, R1, RP, ZP, LP1, LP2LNP, RP3, RN, and ZNPare defined herein, their preparation, pharmaceutical compositions, and methods of use.
REFERENCES:
patent: 6218430 (2001-04-01), Allegretto et al.
patent: 6706725 (2004-03-01), Bernardon
patent: 2006/0094778 (2006-05-01), Nagpal et al.
patent: 2006/0135484 (2006-06-01), Nagpal et al.
patent: 2006/0287536 (2006-12-01), Dahnke et al.
patent: 2006/0293385 (2006-12-01), Gajewski et al.
patent: 2007/0105951 (2007-05-01), Gajewski et al.
patent: 2007/0106095 (2007-05-01), Lu et al.
patent: 2007/0149810 (2007-06-01), Lu et al.
patent: WO 2004/048309 (2004-06-01), None
patent: WO 2005/051893 (2005-06-01), None
patent: WO 2006/069154 (2006-06-01), None
Boehm, M.F. et al, “Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3”, Chemistry and biology, Current Biology, London, GB, vol. 6, No. 5, May 1999, pp. 265-275, XP004881420, ISSN: 1074-5521.
Nagpal, S. et al. “Vitamin D Analogs: Mechanism of Action of Therapeutic Applications”,Curr. Med. Chem. 2001, 1661-1679, vol. 8.
Bouillon R., et al. Structure-Function Relationships in the Vitamin D Endocrine System, Endocrine Rev. 1995, 200-257, vol. 16.
Swann et al. “Rational Design of Vitamin D3 Analogues Which Selectively Restore Activity to a Vitamin D Receptor Mutant Associated with Rickets”Org. Lett. 2002, p. 1863- 3866 vol. 4.
Swann et al. “Structure-Based Design of Selective Agonists for a Rickets-Associated Mutant of the Vitamin D Receptor”J. Am. Chem. Soc. 2002 13795-13805, vol. 124.
Basak, et al., “Comparative effects of calcipotriol and betamethasone 17-valerate solution in the treatment of seborrhoeic dermatitis of the scalp,”European Academy of Dermatology and Venereology JEADV, vol. 15, pp. 77-92 (2001).
Böhm, et al., “Disseminated superficial actinic porokeratosis: Treatment with topical tacalcitol,”Journal of the American Academy of Dermatology, vol. 40, pp. 479-480.
Cunningham, et al., “Topical calcipotriene for morphea/linear Scleroderma,”Journal of the American Academy of Dermatology, vol. 39, pp. 211-215 (1998).
Harrison, “Disseminated superficial actinic porokeratosis responding to calcipotriol,”Clinical Exp. Dermatol., vol. 19, No. 1, p. 95 (1994).
Lin, et al., “The pleiotropic actions of vitamin D,”BioEssays, vol. 26, pp. 21-28 (2003).
Lu, et al., “Transcriptional Profiling of Keratinocytes Reveals a Vitamin D-Regulated Epidermal Differentiation Network,”The Journal of Investigative Dermatologyvol. 124, pp. 778-785 (2005).
Nakayama, et al., “Four cases of sebopsoriasis or seborrheic dermatitis of the face and scalp successfully treated with 1a-24(R)-dihydroxycholecalciferol (tacalcitol) cream,”European Journal of Dermatologyvol. 10, No. 7, pp. 528-532, (2000).
Sapadin, et al., “Treatment of Scleroderma,”Arch Dermatology, vol. 138, pp. 99-105 (2002).
Sato, et al., “Epidermal Growth Factor and 1α, 25-Dihydroxyvitamin D3Suppress Kipogenesis in Hamster Sebaceous Gland Cells In Vitro,”The Society of Investigative Dermatologyvol. 117, pp. 965-970 (2001).
Yee, et al., “Vitamin D Receptor Modulators for Inflammation and Cancer,”Mini-Reviews in Medicinal Chemistry, vol. 5, No. 8, pp. 761-778 (2005).
Zasloff, “Sunlight, Vitamin D, and the Innate Defenses of the Human Skin,”The Society for Investigative Dermatology, vol. 125, pp. xi125, pp. xvi-xvii (2005).
Zinser, et al., “Vitamin D3receptor ablation sensitizes skin to chemically induced tumorigenesis,”Carcinogenesis, vol. 23, No. 12, pp. 2103-2109 (2002).
Hayashi, N. et al., “Comedolytic effect of topically applied active vitamin D3 analogue on pseudocomedones in the rhino mouse.” British Journal of Dermatology, 2006, 155, pp. 895-901.
Gossett Lynn Stacy
Lopez Jose Eduardo
Warshawsky Alan M.
Yee Ying Kwong
Eli Lilly and Company
Katakam Sudhakar
Myers James B.
LandOfFree
Vitamin D receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vitamin D receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vitamin D receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2674504